LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Average Rating of “Moderate Buy” from Brokerages

LifeStance Health Group, Inc. (NASDAQ:LFST) has earned an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $9.75.

Several equities research analysts have recently weighed in on the company. Barclays upped their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, March 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of LifeStance Health Group in a report on Wednesday, May 27th. BTIG Research upped their price target on shares of LifeStance Health Group from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Zacks Research raised LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a report on Monday, April 27th. Finally, The Goldman Sachs Group assumed coverage on shares of LifeStance Health Group in a research note on Friday, June 5th. They set a “neutral” rating and a $9.00 target price on the stock.

Insider Buying and Selling at LifeStance Health Group

In other news, Director Robert Bessler sold 894,337 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the completion of the transaction, the director owned 539,763 shares in the company, valued at approximately $5,467,799.19. This trade represents a 62.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Darren M. Black sold 5,899,661 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the sale, the director owned 23,310,115 shares of the company’s stock, valued at $186,947,122.30. The trade was a 20.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 7,762,394 shares of company stock valued at $64,107,859. 3.20% of the stock is owned by insiders.

Hedge Funds Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Larson Financial Group LLC grew its holdings in shares of LifeStance Health Group by 19,952.6% during the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after buying an additional 3,791 shares in the last quarter. KBC Group NV bought a new stake in shares of LifeStance Health Group during the 1st quarter worth about $29,000. EverSource Wealth Advisors LLC grew its holdings in LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after purchasing an additional 5,404 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after buying an additional 7,987 shares during the last quarter. Finally, Assetmark Inc. increased its stake in shares of LifeStance Health Group by 17.0% in the first quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after purchasing an additional 1,367 shares during the period. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

LifeStance Health Group Price Performance

Shares of LifeStance Health Group stock opened at $11.43 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $11.48. The stock has a market capitalization of $4.43 billion, a P/E ratio of 190.50 and a beta of 1.12. The business’s fifty day moving average price is $8.15 and its 200 day moving average price is $7.34.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The firm had revenue of $403.48 million during the quarter, compared to the consensus estimate of $387.46 million. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. As a group, research analysts anticipate that LifeStance Health Group will post 0.12 earnings per share for the current year.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.